Peter Attia· MD
my understanding of the clinical and the literature in humans is that for most cancers once it's reached the point of diagnosis that rapamycin is disappointing in its effectiveness it's not particularly effective
Loading…
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
my understanding of the clinical and the literature in humans is that for most cancers once it's reached the point of diagnosis that rapamycin is disappointing in its effectiveness it's not particularly effective
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
So my bet would be that in the case of cancer, you're not going to... You're not going to cure cancer once you've got it, but you probably... But I also don't think you're going to modulate the incidence, like the mutational frequencies that are giving you cancer, right?
my understanding of the clinical and the literature in humans is that for most cancers once it's reached the point of diagnosis that rapamycin is disappointing in its effectiveness it's not particularly effective
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.